Tamoxifen and Estrogen Have Similar Effects on the Brain 

Behind the Cancer Headlines

April 18, 2002

A new study suggests that neither tamoxifen nor estrogen has a negative impact on brain chemistry in elderly women. These findings may quell concerns about the safety of using tamoxifen to reduce breast cancer risk in elderly women, say Thomas Ernst, Ph.D., of Brookhaven National Laboratory in New York, and coworkers from the Harbor-UCLA Research and Education Institute in Torrance, Calif., in the April 17 issue of the Journal of the National Cancer Institute

Past studies have suggested that estrogens may improve brain functioning, possibly by blocking neural cell death caused by oxidation. However, some studies have suggested that tamoxifen, which blocks estrogenís stimulatory effects in breast cancer, may block estrogenís beneficial effects on the brain and possibly contribute to cognitive decline. 

To study tamoxifenís effect on brain chemistry in elderly women, Ernst and his coworkers used a brain imaging technique to compare levels of myo-inositol, a chemical that increases in response to brain injury, among 16 breast cancer survivors who had been treated with tamoxifen for at least 2 years; 27 healthy women who had been treated with preventive estrogen replacement therapy for at least 2 years; and 33 healthy women who had not received any treatment. All of the women were between the ages of 65 and 80 and did not have any neurologic diseases. 

The researchers found that women who had been treated with tamoxifen had lower levels of myo-inositol in the brain than the untreated women. Women who took estrogen also had lower levels of the chemical. Myo-inositol levels were lowest among women who had been treated with tamoxifen for longer periods of time. 

The authors conclude from the lower levels of myo-inositol in women treated with tamoxifen or estrogen that "both [tamoxifen and estrogen] may be neuroprotective and may have favorable modulatory effects on aging." They note, however, that future studies are necessary to look at the long-term effects of such therapies on cognitive function. 

In an accompanying editorial, Dr. Patricia Ganz of the University of California Los Angeles Jonsson Comprehensive Cancer Center wrote, "it is highly speculative to interpret [these findings] as indicative of neuroprotection." They note that "it is important to consider alternative explanations for these results that take into account all of what we know about the physiologic effects of estrogen in women, as well as the relationship between lifelong exposure to estrogen and the risk for breast cancer." 

Ganz pointed out that two ongoing studies, the Womenís Health Initiative Memory Study trial and the Study of Tamoxifen and Raloxifene, may provide more definitive answers about the value of hormone replacement therapy as a neuroprotective agent. "In a few years, we may have reliable information about the neurocognitive effects of estrogen and tamoxifen on the brain," she wrote. 



Brookhaven National Laboratory (http://www.bnl.gov)

UCLA Jonnson Comprehensive Cancer Center (http://www.cancer.mednet.ucla.edu)

Journal of the National Cancer Institute, April 17, 2002; 94:592-597

Return to Breast Cancer